00:05:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-06-12 X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018


ListaSmall Cap Stockholm
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2024-01-15 16:08:00

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received an awarding of a public tender for rapid AST instruments and consumables issued by Fondazione PTV – Tor Vergata in Rome, Italy.

The tender has a validity for five years and a total value of EUR 600,000 and the company expects the formalization of the awarding in 35 days. The equipment will be used at the Policlinico Tor Vergata University of Rome.

Franco Pellegrini, General Manager for Italy/Southern Europe commented, “We are extremely pleased with the outcome of this project. Several companies have been involved in the bidding and ASTar has been selected as preferred system based on the highest score between technical and pricing criteria. This is the first evidence of the proven competitiveness of our solution and an important milestone for future tenders and projects to come”.
"It feels really good to share the news that we won the first tender we participated in. We started earlier in Italy compared to our distributor markets and therefore expect to be able to share more positive news in other geographies going forward. Sales cycles are indeed long, but at the same time we see that the tender in Italy is stimulating more tenders, which indicates that the market is starting to see the value of rapid AST. ASTar has performed strongly in the evaluations with customers during the year and it is nice to see that it is now is starting to bear fruit. I also hope that this gives our shareholders the first proof that they have invested in a company with a competitive product," said Jonas Jarvius, CEO and President at Q-linea.  
About ASTar Instruments and ASTar BC G-Kit 
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.  
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.